Catalyst Pharmaceuticals, Inc. 2025 10-K/A – Key Details for Investors

Overview and Amendment

Catalyst Pharmaceuticals, Inc. filed its 10-K/A Annual Report for the fiscal year ended December 31, 2025, amending its original 10-K to include critical Part III disclosures relating to corporate governance, executive compensation, beneficial ownership, related party transactions, and principal accountant fees. The amendment does not alter previously reported financial results or include new financial statements, but it contains information that can influence shareholder decisions and potentially impact the share price.

Corporate Structure and Governance

• Company Profile: Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), headquartered in Coral Gables, FL, specializes in pharmaceutical preparations, focusing on rare diseases.
• Key Directors: The board features a mix of independent and non-independent directors, including Non-Executive Chairman and co-founder Patrick J. McEnany (age 78), reflecting deep experience in pharma and governance.
• Governance Framework: The company maintains robust governance policies, including a code of ethics, audit committee, compensation committee, corporate governance and nominating committee, and insider trading policy. These policies are accessible online and updated within five business days following amendments or waivers.
• Risk Oversight: Risk management is handled at the board level, with regular executive sessions among independent directors to provide feedback to management.

Executive Compensation – Key Price Sensitive Details

Compensation Structure: The compensation philosophy is designed to align executive incentives with shareholder value creation, using a blend of base salary, annual cash bonuses, and equity incentives.

• Compensation Peer Group: The company benchmarks its executive compensation against a peer group including Acadia Pharmaceuticals, Amicus Therapeutics, Amphastar Pharmaceuticals, BioCryst Pharmaceuticals, and others.
• 2025 Bonus Targets: The executive bonus pool is tied to achieving total revenues of at least \$573.5 million, including FIRDAPSE net revenues of \$362.9 million and AGAMREE net product revenues of \$122.1 million. Additionally, acquisition of a significant company or de-risked late-stage orphan asset is a corporate goal.
• Stock Incentive Plan: As of April 27, 2026, 12,254,851 stock options (7,400,967 exercisable) and 714,953 restricted stock units (none vested) are outstanding. The closing price on NASDAQ was \$29.27/share.

Potentially Price Sensitive Information

• Large Executive Equity Grants: The significant value of equity awards (stock options and RSUs) granted to senior executives signals management confidence in long-term growth, but also introduces dilution risk for shareholders.
• Revenue and Acquisition Targets: The bonus structure is highly dependent on meeting revenue milestones and successful acquisition of strategic assets. Failure or success in these areas could materially affect share value.
• Change-in-Control Provisions: All unvested equity awards held by executives will immediately vest upon a change in control, potentially triggering substantial payouts and affecting the company’s attractiveness in M&A scenarios.
• Peer Group Compensation: The company’s compensation practices are competitive with industry peers, which may affect investor perceptions regarding talent retention and cost management.
• Outstanding Shares: As of April 27, 2026, 122,346,043 shares of common stock were outstanding, indicating the company’s capitalization and potential for future dilution.

Corporate Governance & Compliance

• Section 16(a) Compliance: All executive officers, directors, and >10% stockholders complied with SEC filing requirements in 2025, suggesting robust governance.
• Audit Committee Financial Expert: Donald A. Denkhaus is designated as an “audit committee financial expert,” enhancing the credibility of financial oversight.
• Insider Trading Policy: Comprehensive insider trading policy applies to all insiders; available for review as part of the company’s commitment to transparency.

Conclusion – Investor Takeaways

Catalyst Pharmaceuticals’ amended 10-K/A delivers crucial details on executive compensation, governance, and incentive structures tied to aggressive revenue and acquisition goals. The generous equity grants and change-in-control provisions could have significant implications for share value, especially if the company meets or fails to meet revenue targets or becomes an M&A target. Investors should monitor progress against these goals and assess the impact of executive incentive alignment on long-term shareholder value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All information is based on public filings as of April 30, 2026. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. Catalyst Pharmaceuticals’ future performance may differ materially from historical results and forward-looking statements contained herein.

View CATALYST PHARMACEUTICALS, INC. Historical chart here